Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

ABSTRACT:

Objective

To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD).

Design

Randomized, double-blind, placebo-controlled trial.

Setting

Clinical research unit of a Veterans Affairs medical center.

Participants

The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n = 64) or mild to moderate AD (n = 40). Intervention  Participants received placebo (n = 30), 20 IU of insulin (n = 36), or 40 IU of insulin (n = 38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington).

Main outcome measures

Primary measures cons

SUBMITTER: Craft S 

PROVIDER: S-EPMC3260944 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature